Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Polyepitope DNA Vaccine in TNBC
NCT02348320Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2015
- Primary completion
- Mar 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of polyepitope neoantigen dna vaccine in triple-negative breast cancer (TNBC), sponsored by Washington University School of Medicine. Primary endpoint: Safety of the personalized polyepitope DNA vaccine strategy at 52 weeks. Started Jun 2015; status: completed.
02
Drugs
polyepitope neoantigen dna vaccine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02348320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348320.